Joshua Boger - Vertex Pharmaceuticals Insider

VRTX -- USA Stock  

USD 174.82  0.23  0.13%

  Chairman
Dr. Joshua S. Boger, Ph.D., is an Independent Director of Vertex Pharmaceuticals Incorporated. Dr. Boger is the founder of Vertex and was a director since our inception in 1989. He was our Chief Executive Officer from 1992 through May 2009. He was our Chairman of our board of directors from 1997 until May 2006 and our President from our inception until December 2000, and from 2005 through February 2009. He was our Chief Scientific Officer from 1989 until May 1992. Prior to founding Vertex in 1989, Dr. Boger held the position of Senior Director of Basic Chemistry at Merck Sharp Dohme Research Laboratories in Rahway, New Jersey, where he headed both the Department of Medicinal Chemistry of Immunology Inflammation and the Department of Biophysical Chemistry
Age: 63  Chairman Since 2009      
617-341-6100  http://www.vrtx.com
Boger holds a B.A. in chemistry and philosophy from Wesleyan University and M.S. and Ph.D. degrees in chemistry from Harvard University.

Joshua Boger Latest Insider Activity

Management Efficiency

The company has return on total asset (ROA) of 8.49 % which means that it generated profit of $8.49 on every $100 spent on asset. This is normal as compared to the sector avarege. Similarly, it shows return on stockholders equity (ROE) of 10.67 % meaning that it created $10.67 on every $100 dollars invested by stockholders.
The company currently holds 592.73 M in liabilities with Debt to Equity (D/E) ratio of 21.8 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Vertex Pharmaceuticals Incorporated has Current Ratio of 3.6 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 7 records

CHAIRMAN Since

Gengchen HanOrigin Agritech Limited
2016
Clay SiegallSeattle Genetics
2004
Michael McCallisterZoetis
2015
Yasheng YangOrigin Agritech Limited
2010
Ronan OCaoimhTrinity Biotech plc
2011
Josef RickenbachPAREXEL International Corporati
2012
Jon SaxeSciClone Pharmaceuticals
2009

Entity Summary

Vertex Pharmaceuticals Incorporated, a biotechnology company, develops medicines for serious diseases. The company was founded in 1989 and is headquartered in Boston, Massachusetts. Vertex Pharmaceuticals operates under Biotechnology classification in USA and traded on NASDAQ. It employs 2300 people.Vertex Pharmaceuticals Incorporated (VRTX) is traded on NASDAQ in USA. It is located in 50 Northern Avenue and employs 2,300 people.

Vertex Pharmaceuticals Leadership Team

Paul Silva, Senior Vice President Corporate Controller
William Young, Independent Director
David Altshuler, Independent Director
Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer
Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development
Elaine Ullian, Co-Lead Independent Director
Michael Parini, Executive Vice President and Chief Legal Officer
Alan Garber, Independent Director
Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value
Joshua Boger, Executive Director and Chairman of Science and Technology Committee
David Greenway, Director
Bruce Sachs, Co-Lead Independent Director
Margaret McGlynn, Independent Director
Michael Partridge, Vice President - Investor Relations
Yuchun Lee, Independent Director
Sangeeta Bhatia, Director
Kimberly White, Senior Vice President and Chief Communications Officer
Stuart Arbuckle, Chief Commercial Officer and Executive VP
Thomas Graney, CFO, Senior Vice President
Terrence Kearney, Independent Director
Ian Smith, CFO, Executive Vice President
Jeffrey Leiden, Chairman of the Board and Presidentident, CEO

Stock Performance Indicators

Did you try this?

Run Portfolio Quick Import Now
   

Portfolio Quick Import

Import or update all your transactions via one easy-to-use interface
All  Next Launch Portfolio Quick Import

Also Currentnly Active

Purchased over 500 shares of
few days ago
Traded for 6.08
Purchased over 500 shares of
few days ago
Traded for 6.08
Purchased over 100 shares of
few days ago
Traded for 2.17
Also please take a look at World Market Map. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.